The clinical heterogeneity of entirely nonenhancing CNS lymphoma: a case series

Stephen G Bowden, Daniel N Munger, Jaclyn Thiessen, S Cody Schoettler Woll, Seunggu J Han, Edward A Neuwelt, Ramon F Barajas & Prakash Ambady*

1Department of Neurological Surgery, Oregon Health & Science University, Portland, OR 97239, USA
2Department of Radiology, Oregon Health & Science University, Portland, OR 97239, USA
3Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA
*Author for correspondence: ambady@ohsu.edu

CNS lymphoma often presents with atypical imaging characteristics leading to delay in diagnosis and initiation of treatment. Among the most rarely reported of these is entirely nonenhancing CNS lymphoma, which is estimated at an incidence of about 1%. Here, we present three cases of nonenhancing CNS lymphoma in immune competent patients at both initial presentation and recurrence and in primary as well as secondary CNS lymphoma. Diffusion- and perfusion-weighted imaging was found helpful in diagnosis in some cases.

First draft submitted: 17 August 2020; Accepted for publication: 19 November 2020; Published online: 16 December 2020

Keywords: CNS lymphoma • immunocompetent • neuroradiology • nonenhancing

The diagnosis of CNS lymphoma is a distinct challenge and often delayed due to a heterogeneity in clinical presentation, radiologic characteristics and prediagnosis management [1,2]. The typical MRI characteristics of primary CNS lymphoma (PCNSL) in both immunocompetent and immunocompromised patients are relatively well-established. Immune competent patients typically present with single or multiple homogeneously contrast-enhancing lesions in the periventricular white matter [3–9], whereas immunocompromised patients typically demonstrate ring-like enhancement [5,8,10]. However, as many as 25% of patients have ‘atypical’ radiologic presentations, encompassing a broad range of imaging findings [3]. Further, there are few reports on imaging patterns in recurrence or relapse [11].

Entirely nonenhancing CNS lymphoma remains among the most rarely reported of these atypical presentations, limited to case reports or larger case series estimating a prevalence of 1–3% (Table 1) [2–5,12–15]. Here, we present the cases of three immunocompetent patients with CNS lymphoma recently treated at our hospital who presented with nonenhancing lesions either initially, at the time of recurrence or both.

Case descriptions

Case #1
A woman in her 70s with Type 2 diabetes, hypertension, hypothyroidism and symptomatic bradycardia requiring a pacemaker presented to another hospital with several months of progressive truncal ataxia, lower extremity weakness, fatigue and unintentional weight loss. MRI, obtained 2 weeks later, demonstrated nonenhancing T2 hyperintensity in the corpus callosum and centrum semiovale without diffusion restriction (Figure 1A). Her symptoms continued to progress over the next 2 months while a broad work-up of possible rheumatologic, infectious, autoimmune and inflammatory causes was completed without diagnosis. A second MRI, approximately 3 months after initial presentation, demonstrated expansion of the FLAIR hyperintensity as well as development of scattered regions of restricted diffusion and contrast enhancement in a similar distribution (Figure 1B). Around this time, she became increasingly confused and was transferred to our inpatient neurology service for an expedited work-up that included leukemia/lymphoma panel, cerebrospinal fluid cytology, slit-lamp examination and skin punch biopsy – all of which were nondiagnostic.

Given the lack of a diagnosis and suspicion for malignancy, she underwent a right frontal needle biopsy. Pathology demonstrated diffuse large B-cell lymphoma. Staging imaging showed no systemic disease. She was initiated on
Table 1. A summary of previously reported cases of entirely nonenhancing CNS lymphoma.

| Author        | Year | Age | Gender | Diffusion restriction? | IS? | Subtype | Time of diagnosis | Diagnosis | Ref.        |
|---------------|------|-----|--------|-------------------------|-----|---------|------------------|-----------|-------------|
| DeAngelis    | 1993 | 60  | M      | No                      |     |         | Recurrence       | Autopsy   | [4]         |
|              |      | 80  | F      | No                      |     |         | Recurrence       | Autopsy   |             |
| Carlson       | 1996 | 76  | F      | No                      |     |         | Primary           | Brain biopsy | [15]       |
| Kuker et al. | 2005 |     |        | Primary                 |     |         | Initial           | Brain biopsy | [13]       |
| Lachenmayer et al. | 2011 | 81  | F      | No                      |     |         | Primary           | Brain biopsy | [14]       |
| Fischer et al. | 2011 | 52  | M      | Yes                     |     |         | Recurrence        | Autopsy    | [16]       |
| Hu et al.     | 2019 | 61  | M      | No                      |     |         | Primary           | Brain biopsy | [12]       |
| Lin et al.    | 2020 | 71  | F      | Yes                     |     |         | No                | Brain biopsy | [3]        |
| Current article | 2021 | 63  | F      | No                      |     |         | No                | Primary    |             |
|              |      | 73  | M      | Yes                     |     |         | No                | Secondary  | CSF flow cytometry |

F: Female; IS: Immunosuppressed; M: Male.

Figure 1. Axial slices from MRI with left: FLAIR, middle: postgadolinium T1; right: apparent diffusion coefficient. (A) MRI on initial presentation demonstrating a T2/FLAIR hyperintense lesion within the splenium that shows some diffusion restriction but does not enhance with contrast. (B) Repeat MRI after 3 months of continued neurologic decline showing the development of T2/FLAIR hyperintensity with patchy enhancement and some diffusion restriction in the bilateral centrum semiovale.

intravenous (iv.) high-dose rituximab and methotrexate infusions, but her hospital course was soon complicated by pneumonia causing severe encephalopathy and acute hypoxemic respiratory failure, requiring transfer to the intensive care unit. Her oxygenation quickly improved with antibiotics and pulmonary care; however, her family ultimately decided that further chemotherapy would not be in line with her goals of care. She was discharged to home hospice 1 month after admission.

Case #2
A woman in her 60s with a history of chronic hepatitis C and cirrhosis presented to an outside hospital with 3 years of progressive vision loss and 2 weeks of confusion and right hemiparesis. MRI revealed bilateral, asymmetrically distributed T2 signal abnormality within the subcortical white matter, deep structures and brainstem with evidence
Heterogeneity of nonenhancing CNS lymphoma 

Case Series

Figure 2. Axial slices from Case #2 MRI. (A) Axial slices from MRI with left: FLAIR, right: apparent diffusion coefficient. MRI after 2 weeks of confusion and right hemiparesis demonstrating diffuse T2/FLAIR hyperintense, nonenhancing lesion with mixed diffusion restriction in the left basal ganglia and subcortical white matter. (B) Axial slices from MRI with left: T2, right: cerebral blood volume. Surveillance imaging off treatment demonstrated bulky T2 hyperintensity in the splenium of the corpus callosum without enhancement or elevated cerebral volume. (C) Imaging of frank recurrence with large, bulky T2/FLAIR hyperintensity in the right basal ganglia and subcortical white matter without definitive enhancement but with markedly elevated cerebral blood volume.

of mass effect as well as vague areas of contrast enhancement in the left thalamus/midbrain and posterior corpus callosum (Figure 2A). Flow cytometry from a vitreous biopsy was unremarkable. She underwent a needle biopsy of the left caudate head and slit-lamp examination and was diagnosed with PCNSL with ocular involvement. She was treated with induction iv. chemotherapy and intra-arterial methotrexate. Thereafter, she was transferred to our hospital, where she completed four cycles of iv., intra-arterial and intra-ocular chemotherapy with resolution of
pathologic enhancement on imaging. After 2 subsequent years off treatment, surveillance imaging demonstrated focal enlargement of a T2 hyperintensity within the corpus callosum and corresponding elevated cerebral blood volume (Figure 2B). This finding was felt to be concerning for, but not definitive of, nonenhancing disease recurrence. She resumed iv. rituximab until follow-up imaging 7 months later was definitive for disease progression on T2, postcontrast and perfusion sequences (Figure 2C). She then received 14 cycles of iv. high dose methotrexate and rituximab with good response. She continues to receive maintenance rituximab every 3 months and has had stable imaging for 2 subsequent years.

Case #3
A man in his 70s with a history of gout, mild cognitive impairment and systemic B-cell lymphoma underwent systemic chemotherapy and CNS prophylaxis with complete systemic response. Seven months later, he presented with headaches, left facial numbness and left nasolabial flattening. He was found to have a nonenhancing, expansile T2/FLAIR hyperintense lesion in the rostral medulla/pons without clearly reduced diffusion (Figure 3A), felt to represent CNS lymphoma despite negative cerebrospinal fluid cytology. He received induction and maintenance chemotherapy, the latter of which was complicated by a large subacute subdural hematoma requiring surgical evacuation. Thereafter, he transferred his care to our institution and remained clinically stable off therapy. After 8 months of surveillance, he was hospitalized with generalized weakness, abdominal pain, nausea and shortness of breath after finding a new nonenhancing medullary, T2/FLAIR hyperintense lesion with normal cerebral blood volume (Figure 3B). A lumbar puncture after admission to the hospital was positive for B-cell lymphoma on flow cytometry. He elected to pursue further treatment with methotrexate and rituximab, but developed acute respiratory distress and expired prior to initiating chemotherapy.

Discussion
Gadolinium-enhanced MRI remains the imaging modality of choice for initial work-up and response assessment. CNS lymphoma in immune competent patients typically presents with homogeneously enhancing lesions. The volume of enhancement is frequently used as a surrogate for tumor burden in the CNS and changes in the enhancing abnormalities on gadolinium enhanced MRI remain the most important radiologic criteria for response assessment [17]. Autopsy studies have suggested that CNS lymphoma is in fact a whole brain disease and, in reality,
pathologic enhancement represents only regions of blood–brain barrier disruption, which does not correlate with the true extent of disease [18]. The significance of the nonenhancing T2 signal abnormalities in CNS lymphoma remains unclear.

Here, we present three distinctive cases of entirely nonenhancing CNS lymphoma to underline the radiologic heterogeneity of clinical scenarios in which it may arise. This series includes entirely nonenhancing lesions at incident discovery in both primary and secondary CNS lymphoma and at recurrence of both previously nonenhancing and previously enhancing lesions. In doing so, we add to previous reports of nonenhancing CNS lymphoma by reporting the first cases of a nonenhancing secondary CNS lymphoma and a nonenhancing recurrence of previously nonenhancing PCNSL to our knowledge.

All three patients were immunocompetent and defied the most common radiologic characteristics – homogeneous enhancing lesion(s) in the periventricular white matter [3–9] – of this population in several ways. Case 1 presented with initially nonenhancing disease, for which lymphoma remained low on the differential until a thorough work-up had been completed. Ultimately, a clinical decline 2 months later led to the discovery of pathologic contrast enhancement on follow-up imaging that was evaluated with a brain biopsy. Case 2's extensive T2/FLAIR abnormality with a relative paucity of enhancement also conflicts with expected findings for CNS lymphoma. Likely due to the concerning volume of disease and the wisp of enhancement, a brain biopsy was performed early in her diagnostic work-up. Her recurrence was initially interpreted cautiously, due to its disparate radiologic characteristics, until she ultimately developed frank recurrence with enhancement despite treatment. Case 3 is atypical for its lack of enhancement, location, isolated brainstem disease and parenchymal rather than leptomeningeal involvement in a secondary CNS lymphoma. Fortunately, treatment was initiated quickly as his history of recently treated systemic lymphoma rendered a narrow differential diagnosis. The former two cases, together with a similar previous report of initially nonenhancing CNS lymphoma [12], may suggest that all such nonenhancing disease will eventually enhance, the mechanisms of which are beyond the scope of this report.

As in our first case, diagnostic delay is a common problem in PCNSL, yet remains poorly studied [1]. Only certain neurologic symptoms are associated with a longer time to imaging from initial presentation, while the withdrawal or corticosteroids prior to brain biopsy and a need for second brain biopsy are associated with a delay in achieving diagnosis [2]. While there is no known association between atypical imaging characteristics and diagnostic delay, it is certainly a potential consequence of such an unusual presentation as entirely nonenhancing disease [14]. To this end, our first patient in this series corroborates previous reports of protracted disease courses prior to diagnosis and initiation of therapy [4,12]. The clinical implications of such delays remain unclear; however, this series supplements mounting evidence that thorough evaluation for lymphoma should be considered early even in instances of atypical imaging.

As part of the effort in hastening diagnosis, advanced imaging such as diffusion- and perfusion-weighted sequence MRI have been explored in search of a noninvasive biomarker for CNS lymphoma with mixed success. Diffusion-weighted imaging can adequately distinguish between CNS lymphoma and high-grade gliomas [19–21], metastases [21] and tumefactive demyelinating disease [6]. Beyond this, it may even predict clinical outcomes [22]. Our first case demonstrated reduced diffusion at initial imaging, but unfortunately was not referred to our institution until 2 months later, by which time her lesions began to enhance. In contrast, there was no abnormally reduced diffusion at the time of presentation in the second and third cases. Perfusion-weighted imaging can also differentiate between lymphoma and high-grade tumors, such as glioblastoma and metastasis [21,23]. Cerebral blood volume aided in confirming a suspected recurrence in our second case; however, it remained normal in our first case's recurrence.

There is more limited and less compelling evidence for evaluating atypical CNS lymphoma with such advanced imaging; however, Reiche et al. [24] found diffusion-weighted imaging useful in four patients with atypical features, but notably only one of the patients described had entirely nonenhancing disease. Brain biopsy was delayed in that patient until a neurologic decline 2 weeks later, at which time repeat imaging demonstrated abnormal enhancement. Such a delay is again similar to our third case description. Some success was reported in a single case by Kawai et al. [25] where decreased 18F-fluorodeoxyglucose transport and increased hexokinase activity on 18F-fluorodeoxyglucose-PET raised suspicion for a neoplastic process in an otherwise benign-appearing, nonenhancing lesion. These findings led to a brain biopsy and diagnosis of lymphoma without delay. Unfortunately, this has not been duplicated to our knowledge and a follow-up study of 17 patients demonstrated little utility for PET in atypical PCNSL [26].
Recognizing relapse is a separate and distinct problem from that of primary recognition. The spatial characteristics of relapse are relatively well described, with a preponderance of distant rather than local relapse [11,27,28]. However, there are no reports of other features of imaging recurrence in CNS lymphoma to our knowledge and, importantly, the aforementioned studies were limited to patients with distinct contrast-enhancing lesions. The spatiotemporal and radiologic characteristics of relapsed CNS lymphoma with atypical imaging features merits further study. In this context, treatment-related T2 signal abnormalities after high-dose methotrexate based regimens may further complicate response assessment [29]. The second and third cases in this series highlight the variability that may be seen in such relapses of atypical disease, with both local and distant recurrence, as well as disparate imaging features. These cases underscore the need for a low threshold to pursue diagnosis and initiate therapy in order to optimize patient outcomes.

Conclusion

There is great radiologic heterogeneity in nonenhancing CNS lymphoma at both initial presentation and recurrence. Advanced imaging modalities, including diffusion- and perfusion-weighted sequences, may inform the differential diagnosis and prevent diagnostic delay.

Executive summary

- Both primary and secondary CNS lymphoma can be entirely nonenhancing at presentation.
- Relapse or recurrence should be considered with T2 hyperintense abnormalities in patients with a history of CNS lymphoma, even if it was previously nonenhancing.
- CNS lymphoma should be considered early in diagnostic work-up of entirely nonenhancing, T2 hyperintense abnormalities in immune competent patients.
- Diffusion- and perfusion-weighted as well as PET imaging can supplement common MRI sequences in informing diagnosis.
- Delay in diagnosis and treatment initiation may contribute to worse outcomes in CNS lymphoma.

Author contributions

SG Bowden: conception and design of idea; acquisition, analysis and interpretation of data; drafting the work and critically revising it; final approval of the version to be published; accountable for all aspects of the work. DN Munger, J Thiessen, SCS Woll: acquisition, analysis and interpretation of data; drafting the work; final approval of the version to be published; accountable for all aspects of the work. SJ Han, EA Neuwelt, RF Barajas, P Ambady: conception and design of idea; drafting the work and critically revising it; final approval of the version to be published; accountable for all aspects of the work.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Informed consent disclosure

The authors state that they have obtained verbal and written informed consent from the patients for the inclusion of their medical and treatment history within this case series.

Open Access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

References

Papers of special note have been highlighted as: • of interest

1. Haldorsen IS, Krossnes BK, Aarseth JH et al. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989–2003: time trends in a 15-year national survey. Cancer 110(8), 1803–1814 (2007).
2. Velasco R, Mercadal S, Vidal N et al. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J. Neurooncol. 148(3), 545–554 (2020).

• Velasco et al. is a recent article that underscores the importance of swift diagnosis in CNS lymphoma and its effect on outcomes while offering explanations for delays in some cases.
3. Lin X, Khan I RA, Seet VHC, Lee HY, Yu WY. Atypical radiological findings of primary central nervous system lymphoma. *Neuroradiology* 62(6), 669–676 (2020).

4. DeAngelis LM. Cerebral lymphoma presenting as a nonenhancing lesion on computed tomographic/magnetic resonance scan. *Ann. Neurol.* 33(3), 308–311 (1993).

5. Haldorsen IS, Krakenes J, Krossnes BK, Mella O, Espeland A. CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989–2003. *AJNR Am. J. Neuroradiol.* 30(4), 744–751 (2009).

6. Lu SS, Kim SJ, Kim N, Kim HS, Choi CG, Lim YM. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions. *AJR Am. J. Roentgenol.* 204(4), 827–834 (2015).

7. Erdag N, Bhorade RM, Alberico RA, Yousuf N, Patel MR. Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. *AJNR Am. J. Neuroradiol.* 26(6), 984–992 (2011).

8. Mansour A, Qandeel M, Abdel-Razeq H, Abu Ali HA. MR imaging features of intracranial primary CNS lymphoma in immune competent patients. *Cancer Imaging* 14(1), 22 (2014).

9. Kaulen LD, Galluzzo D, Hui P et al. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma. *J. Neurooncol.* 144(1), 107–115 (2019).

10. Amjadi P, Fu R, Netto JP et al. Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. *Fluids Barriers CNS* 14(1), 16 (2017).

11. Hu NN, Zhang MM, Chen YY, Zhu BL. Primary central nervous system lymphoma with no enhancement initially and no significant progression over a long term: a case report and review of the literature. *Int. J. Neurosci.* 129(3), 303–307 (2019).

12. Kuker W, Nagole T, Korfel A et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. *J. Neurooncol.* 72(2), 169–177 (2005).

13. Kuker et al. is one of the largest series describing the common and uncommon radiologic features of CNS lymphoma.

14. Lachmanner ML, Blasius E, Niehusmann P et al. Non-enhancing primary CNS lymphoma. *J. Neurooncol.* 101(2), 343–344 (2011).

15. Carlson BA. Rapidly progressive dementia caused by nonenhancing primary lymphoma of the central nervous system. *AJNR Am. J. Neuroradiol.* 17(9), 1695–1697 (1996).

16. Fischer L, Koch A, Schlegel U et al. Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions. *J. Neurooncol.* 102(1), 163–166 (2011).

17. Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. *J. Clin. Oncol.* 23(22), 5034–5043 (2005).

18. Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? *Neurology* 59(10), 1557–1562 (2002).

19. Kickingereeder P, Wiestler O, Sahm F et al. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. *Radiology* 272(3), 843–850 (2014).

20. Toh CH, Castillo M, Wong AM et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. *AJNR Am. J. Neuroradiol.* 29(3), 471–475 (2008).

21. Calli C, Kitis O, Yuntten N, Yurtseven T, Idikel S, Akalin T. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. *Eur. J. Radiol.* 58(3), 394–403 (2006).

22. Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. *AJNR Am. J. Neuroradiol.* 31(1), 60–66 (2010).

23. Hakyemez B, Erdogan C, Bolca N, Yildirim N, Gokalp G, Parlak M. Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. *J. Magn. Reson. Imaging* 24(4), 817–824 (2006).

24. Reiche W, Hagen T, Schuchardt V, Billmann P. Diffusion-weighted MR imaging improves diagnosis of CNS lymphomas. A report of four cases with common and uncommon imaging features. *Clin. Neurol. Neurosurg.* 109(1), 92–101 (2007).

25. Reiche et al. offers evidence to suggest that diffusion-weighted imaging may be beneficial in noninvasively differentiating atypically presenting CNS lymphoma from other diagnoses.

26. Kawai N, Kawanishi M, Tamiya T, Nagao S. Usefulness of [18F]FDG-PET kinetic analysis in non-enhancing primary central nervous system lymphoma: case report. *Ann. Nucl. Med.* 19(5), 415–419 (2005).

27. Watanabe N, Okubo S, Miyake K et al. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. *Ann. Nucl. Med.* 24(5), 335–343 (2010).

28. Patel MP, Kirkpatrick JP, Johnson MO et al. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. *J. Neurooncol.* 147(2), 477–483 (2020).
28. Schulte-Altedorneburg G, Heuser L, Pels H. MRI patterns in recurrence of primary CNS lymphoma in immunocompetent patients. *Eur. J. Radiol.*, 81(9), 2380–2385 (2012).

29. Estephan F, Ye X, Dzaye O et al. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab. *J. Neurooncol.*, 145(3), 461–466 (2019).